AXQ Capital LP Invests $243,000 in Insmed, Inc. $INSM

AXQ Capital LP purchased a new position in Insmed, Inc. (NASDAQ:INSM) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,412 shares of the biopharmaceutical company’s stock, valued at approximately $243,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Legal & General Group Plc grew its position in Insmed by 15.3% in the second quarter. Legal & General Group Plc now owns 207,851 shares of the biopharmaceutical company’s stock worth $20,918,000 after acquiring an additional 27,649 shares in the last quarter. Neo Ivy Capital Management grew its holdings in shares of Insmed by 287.6% in the second quarter. Neo Ivy Capital Management now owns 17,256 shares of the biopharmaceutical company’s stock worth $1,737,000 after purchasing an additional 12,804 shares during the last quarter. DNB Asset Management AS purchased a new position in shares of Insmed in the second quarter worth $208,000. Swiss National Bank boosted its holdings in shares of Insmed by 5.5% during the second quarter. Swiss National Bank now owns 347,400 shares of the biopharmaceutical company’s stock worth $34,962,000 after purchasing an additional 18,100 shares during the period. Finally, Catalyst Funds Management Pty Ltd purchased a new position in shares of Insmed during the second quarter valued at approximately $4,748,000.

Insmed Stock Up 1.0%

Shares of INSM opened at $209.02 on Wednesday. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $209.77. The company has a market cap of $44.58 billion, a PE ratio of -36.61 and a beta of 1.05. The business has a fifty day moving average of $170.30 and a 200 day moving average of $127.60.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same period in the previous year, the business earned ($1.27) EPS. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the sale, the director directly owned 63,729 shares in the company, valued at approximately $12,482,599.23. This represents a 13.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the sale, the insider owned 36,461 shares of the company’s stock, valued at approximately $7,073,434. This represents a 45.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 252,922 shares of company stock worth $43,533,383 over the last quarter. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on INSM shares. Cowen reissued a “buy” rating on shares of Insmed in a research report on Thursday, November 20th. Bank of America upped their price target on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Stifel Nicolaus increased their price objective on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Cantor Fitzgerald began coverage on shares of Insmed in a research report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 target price for the company. Finally, UBS Group lifted their price target on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a report on Friday, October 31st. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $175.53.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.